Back to Search Start Over

Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure

Authors :
Michael R. Gold
Cecilia Linde
William T. Abraham
Stefano Ghio
Ted Plappert
Martin St. John Sutton
John M. Herre
Christian Hassager
Claude Daubert
Luigi Tavazzi
Laura Scelsi
University of Pennsylvania Medical Center
University of Pennsylvania [Philadelphia]
Fondazione IRCCS Policlinico San Matteo [Pavia]
Università di Pavia
GVM Hospitals of Care and Research
Service de cardiologie et maladies vasculaires
Université de Rennes 1 (UR1)
Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes]
Division of Cardiovascular Medicine and the Davis Heart and Lung Research Institute
Ohio State University [Columbus] (OSU)
Division of cardiology
Medical University of South Carolina [Charleston] (MUSC)
Department of Cardiology
Copenhagen University Hospital-Rigshospitalet [Copenhagen]
Copenhagen University Hospital
Sentara Norfolk General Hospital
Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]
This study was supported by Medtronic Inc (Minneapolis, Minn) and the Medtronic Bakken Research Center B.V. in Maastricht, Netherlands.
REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study Group
Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes]
CHU Pontchaillou [Rennes]
Source :
Circulation, Circulation, American Heart Association, 2009, 120 (19), pp.1858-65. ⟨10.1161/CIRCULATIONAHA.108.818724⟩
Publication Year :
2009
Publisher :
HAL CCSD, 2009.

Abstract

Background— Cardiac resynchronization therapy (CRT) improves LV structure, function, and clinical outcomes in New York Heart Association class III/IV heart failure with prolonged QRS. It is not known whether patients with New York Heart Association class I/II systolic heart failure exhibit left ventricular (LV) reverse remodeling with CRT or whether reverse remodeling is modified by the cause of heart failure. Methods and Results— Six hundred ten patients with New York Heart Association class I/II heart failure, QRS duration ≥120 ms, LV end-diastolic dimension ≥55 mm, and LV ejection fraction ≤40% were randomized to active therapy (CRT on; n=419) or control (CRT off; n=191) for 12 months. Doppler echocardiograms were recorded at baseline, before hospital discharge, and at 6 and 12 months. When CRT was turned on initially, immediate changes occurred in LV volumes and ejection fraction; however, these changes did not correlate with the long-term changes (12 months) in LV end-systolic ( r =0.11, P =0.31) or end-diastolic ( r =0.10, P =0.38) volume indexes or LV ejection fraction ( r =0.07, P =0.72). LV end-diastolic and end-systolic volume indexes decreased in patients with CRT turned on (both P P Conclusions— CRT in patients with New York Heart Association I/II resulted in major structural and functional reverse remodeling at 1 year, with the greatest changes occurring in patients with a nonischemic cause of heart failure. CRT may interrupt the natural disease progression in these patients. Clinical Trial Registration— Clinicaltrials.gov Identifier: NCT00271154.

Subjects

Subjects :
Male
MESH: Combined Modality Therapy
Heart disease
MESH: Echocardiography, Doppler
Cardiac Volume
medicine.medical_treatment
heart failure
cardiac resynchronization therapy
Angiotensin-Converting Enzyme Inhibitors
030204 cardiovascular system & hematology
Doppler echocardiography
Severity of Illness Index
ventricular remodeling
MESH: Stroke Volume
Electrocardiography
0302 clinical medicine
[INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing
Medicine
echocardiography
030212 general & internal medicine
New York Heart Association Class I
MESH: Treatment Outcome
MESH: Aged
Ejection fraction
MESH: Middle Aged
medicine.diagnostic_test
Cardiac Pacing, Artificial
MESH: Angiotensin-Converting Enzyme Inhibitors
MESH: Adrenergic beta-Antagonists
MESH: Heart Failure, Systolic
Stroke volume
Middle Aged
Combined Modality Therapy
Echocardiography, Doppler
Treatment Outcome
Cardiology
cardiovascular system
Female
[SDV.IB]Life Sciences [q-bio]/Bioengineering
Cardiology and Cardiovascular Medicine
[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing
medicine.medical_specialty
Adrenergic beta-Antagonists
Cardiac resynchronization therapy
MESH: Ventricular Remodeling
MESH: Cardiac Pacing, Artificial
03 medical and health sciences
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Physiology (medical)
Internal medicine
MESH: Severity of Illness Index
Humans
cardiovascular diseases
Ventricular remodeling
Aged
MESH: Humans
business.industry
MESH: Angiotensin II Type 1 Receptor Blockers
MESH: Cardiac Volume
Stroke Volume
medicine.disease
MESH: Male
MESH: Electrocardiography
Heart failure
business
Angiotensin II Type 1 Receptor Blockers
MESH: Female
Heart Failure, Systolic

Details

Language :
English
ISSN :
00097322 and 15244539
Database :
OpenAIRE
Journal :
Circulation, Circulation, American Heart Association, 2009, 120 (19), pp.1858-65. ⟨10.1161/CIRCULATIONAHA.108.818724⟩
Accession number :
edsair.doi.dedup.....ed0337a29cf9bc3115b58709042e6318